Insider Transactions in Q4 2024 at Maravai Lifesciences Holdings, Inc. (MRVI)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
134,409
+50.0%
|
-
|
|
Dec 09
2024
|
Gregory T Lucier Director |
BUY
Bona fide gift
|
Indirect |
20,645
+50.0%
|
-
|
|
Dec 09
2024
|
Gregory T Lucier Director |
SELL
Bona fide gift
|
Direct |
20,645
-27.25%
|
-
|
|
Nov 15
2024
|
Rebecca Buzzeo Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,363
-1.2%
|
$17,452
$4.42 P/Share
|
|
Nov 12
2024
|
John A De Ford Director |
BUY
Open market or private purchase
|
Direct |
17,500
+19.99%
|
$87,500
$5.75 P/Share
|
|
Nov 11
2024
|
Carl Hull Director |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$875,000
$5.64 P/Share
|
|
Oct 31
2024
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,906
+0.56%
|
$9,530
$5.7 P/Share
|
|
Oct 31
2024
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,848
+0.7%
|
$9,240
$5.7 P/Share
|
|
Oct 31
2024
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
366
+0.16%
|
$1,830
$5.7 P/Share
|
|
Oct 31
2024
|
Andrew Burch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+0.43%
|
$9,205
$5.7 P/Share
|
|
Oct 15
2024
|
William E. Martin Iii Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,843
-4.89%
|
$406,744
$8.29 P/Share
|